CD 581
Latest Information Update: 10 Jan 2008
Price :
$50 *
At a glance
- Originator Galderma
- Class Anti-inflammatories; Antipsoriatics
- Mechanism of Action Lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atopic dermatitis; Inflammation; Psoriasis
Most Recent Events
- 10 Jan 2008 Discontinued - Phase-I for Psoriasis in France (Topical)
- 31 Mar 2000 No-Development-Reported for Atopic dermatitis in France (Topical)
- 31 Mar 2000 No-Development-Reported for Inflammation in France (Topical)